Top Health Care Stocks
Health care stocks were trying to extend their earlier gains this afternoon, with the NYSE Health Care Index climbing almost 0.4% in recent trading while shares of health care companies in the S&P 500 also were up nearly 0.5% as a group.
In company news, Xoma Corp ( XOMA ) again reversed course in Wednesday trading, with the biotech company's shares returning to positive ground after a 10.5% retreat to a session low of $14.42 apiece and regaining the positive momentum that initially followed Swiss drugmaker Novartis AG ( NVS ) last night disclosing a 6.6% equity stake in Xoma.
Novartis acquired 539,131 Xoma shares on August 24, according to yesterday's joint regulatory filing. The companies struck a licensing pact in October 2015 as part of a wider immuno-oncology initiative at Novartis, although the recent stock purchase was instead tied to a separate license agreement executed last month between the firms providing Novartis with an exclusive, global license for Xoma's gevokizumab product candidate.
Xoma received a $16 million upfront payment as part of the gevokizumab license agreement and is eligible for up to $438 million in future payments from Novartis, which also repaid $12 million in debt owed by Xoma to Les Laboratoires Servier. Novartis also paid $5 million total - or about $9.27 per share, a 25% premium to the stock's average closing price over the prior 30 days - in the Aug. 24 stock sale in exchange for commercialization rights to Xoma's IL-1 beta intellectual property portfolio.
Novartis also agreed to extend the maturity date on its prior loan to Xoma by another two years until September 2022.
In other sector news,
(+) VSTM, (+29.4%) Duvelisib drug candidate meets primary endpoint during Phase III testing in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, demonstrating superiority extending progression-free survival compared with another drug, ofatumumab.
(-) PULM, (-11.3%) Licenses its PUR0200 drug candidate to treat chronic obstructive pulmonary disease to the U.K.'s Vectura Group (VEC.L), which will now be responsible for all future development costs. Pulmatrix also receives $1 mln technology-access fee.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.